<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>MHRA</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Biggest overhaul of UK clinical trials rules in 20 years comes into force</title>
      <description>
        <![CDATA[New U.K. clinical trials regulations coming into force today, April 28, aim to reduce the time taken to get approval for studies and introduce a category of lower risk trials which will be automatically assessed in 14 days. The key measure to cut timelines is the Combined Review, under which sponsors will be able to submit a single application for regulatory review by the Medicines and Healthcare products Regulatory Agency and ethics review by the Health Research Authority, the body responsible for managing ethics committees.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730668</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730668-biggest-overhaul-of-uk-clinical-trials-rules-in-20-years-comes-into-force</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Stethoscope-on-UK-flag.webp?t=1764799994" type="image/jpeg" medium="image" fileSize="523217">
        <media:title type="plain">Stethoscope on UK flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Wegovy pricing deal offers UK reimbursement for heart disease</title>
      <description>
        <![CDATA[Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed for the prevention of further serious cardiovascular events in people who have had a heart attack or stroke, or are diagnosed with peripheral arterial disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729982</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729982-wegovy-pricing-deal-offers-uk-reimbursement-for-heart-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Wegovy.webp?t=1691529296" type="image/jpeg" medium="image" fileSize="211081">
        <media:title type="plain">Wegovy </media:title>
        <media:description type="plain">Credit: Novo Nordisk A/S</media:description>
      </media:content>
    </item>
    <item>
      <title>UK’s MHRA sets out new scheme to promote replacement of animal models</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is to offer an early review of nonanimal data to give companies more confidence that evidence generated with new approach methodologies, such as organoids and microphysiological systems, will be accepted as part of marketing authorization applications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729843</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729843-uks-mhra-sets-out-new-scheme-to-promote-replacement-of-animal-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Research-mouse-polygonal-wireframe.webp?t=1748012477" type="image/jpeg" medium="image" fileSize="678701">
        <media:title type="plain">Art concept for mouse model</media:title>
      </media:content>
    </item>
    <item>
      <title>UK sets out regulatory pathway for biologics made in space</title>
      <description>
        <![CDATA[U.K. biopharma is working with the country’s space agency and Civil Aviation Authority (CAA) to plot a route for manufacturing biologic drugs in low earth orbit. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729480</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729480-uk-sets-out-regulatory-pathway-for-biologics-made-in-space</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/planet-earth-space-europe.webp?t=1773347341" type="image/jpeg" medium="image" fileSize="1122080">
        <media:title type="plain">Earth from space</media:title>
      </media:content>
    </item>
    <item>
      <title>Zelluna’s ZI-MA4-1 gains UK CTA clearance for solid tumors</title>
      <description>
        <![CDATA[Zelluna ASA has received approvals from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and research ethics committee for its clinical trial application (CTA) for ZI-MA4-1, Zelluna’s lead T-cell receptor-based natural killer (TCR-NK) product candidate.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728971</guid>
      <pubDate>Mon, 23 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728971-zellunas-zi-ma4-1-gains-uk-cta-clearance-for-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/T-cells2.webp?t=1588881096" type="image/png" medium="image" fileSize="517011">
        <media:title type="plain">T cells </media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA proposes path forward for CE-marked devices </title>
      <description>
        <![CDATA[With CE-marked products accounting for about 90% of medical devices currently used in Great Britain, the Medicines and Healthcare products Regulatory Agency (MHRA) is considering proposals for a path forward that would help the U.K. achieve its goal of becoming a leading country for med-tech access by 2030.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729073</guid>
      <pubDate>Wed, 18 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729073-mhra-proposes-path-forward-for-ce-marked-devices</link>
    </item>
    <item>
      <title>UK reports increase in clinical trial approvals with new rules</title>
      <description>
        <![CDATA[Four years after they were first mooted, the finishing line is in sight for new U.K. clinical regulations, which will come into force on April 28. In the first major update since 2004, about 20% of lower-risk studies are expected to be approved by a fast track, and the Medicines and Healthcare products Regulatory Agency will introduce a 14-day assessment route for phase I healthy volunteer trials, amongst other measures to streamline approvals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728170</guid>
      <pubDate>Fri, 23 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728170-uk-reports-increase-in-clinical-trial-approvals-with-new-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/UK-flag-on-stethoscope.webp?t=1602090629" type="image/png" medium="image" fileSize="394700">
        <media:title type="plain">U.K. flag on stethoscope</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA opens pilot for small firms registering clinical device studies</title>
      <description>
        <![CDATA[The U.K. Medicines and Health Care Products Regulatory Agency provided an update of its guidance for clinical investigations for medical devices and is offering a temporary waiver of the fees for registration of clinical studies to small manufacturers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727799</guid>
      <pubDate>Mon, 12 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727799-mhra-opens-pilot-for-small-firms-registering-clinical-device-studies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-england-london2.webp?t=1588688169" type="image/png" medium="image" fileSize="580024">
        <media:title type="plain">London, England</media:title>
      </media:content>
    </item>
    <item>
      <title>White House steps in on preemption of state AI law </title>
      <description>
        <![CDATA[The Trump administration has made known that it intends to foster rapid adoption of AI, starting with a repeal of an executive order (EO) issued by the Biden administration. Now, the White House has issued an EO that would override state AI law, a move that addresses a task that Congress to date has failed to complete.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727104</guid>
      <pubDate>Fri, 19 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727104-white-house-steps-in-on-preemption-of-state-ai-law</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI_landscape.webp?t=1588275844" type="image/png" medium="image" fileSize="499179">
        <media:title type="plain">AI microchip illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Zelluna files CTA for MAGE-A4-targeting TCR-NK therapy</title>
      <description>
        <![CDATA[Zelluna ASA has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1 (ZIMA-101), the company’s lead candidate. ZI-MA4-1 is a novel MAGE-A4-targeting T-cell receptor-natural killer (TCR-NK) therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727262</guid>
      <pubDate>Thu, 18 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727262-zelluna-files-cta-for-mage-a4-targeting-tcr-nk-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-supply-vessels.webp?t=1683902294" type="image/jpeg" medium="image" fileSize="254242">
        <media:title type="plain">Art concept for tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>NICE to bump cost effectiveness thresholds for HTAs</title>
      <description>
        <![CDATA[The U.K. National Institute for Health and Care Excellence announced an increase in the cost effectiveness thresholds for its health technology assessment program, but this new threshold falls far short of where the figure should be when adjusting for inflation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726444</guid>
      <pubDate>Tue, 02 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726444-nice-to-bump-cost-effectiveness-thresholds-for-htas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-flag-map.webp?t=1588688261" type="image/png" medium="image" fileSize="400329">
        <media:title type="plain">United Kingdom flag, map</media:title>
      </media:content>
    </item>
    <item>
      <title>Tangram seeks clinical trial clearance for TGM-312 for MASH</title>
      <description>
        <![CDATA[Tangram Therapeutics plc has submitted a clinical trial application (CTA) to the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II trial of TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH).]]>
      </description>
      <guid>http://www.bioworld.com/articles/726567</guid>
      <pubDate>Wed, 26 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726567-tangram-seeks-clinical-trial-clearance-for-tgm-312-for-mash</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/fatty-liver-disease.webp?t=1589217291" type="image/png" medium="image" fileSize="932342">
        <media:title type="plain">Liver disease</media:title>
      </media:content>
    </item>
    <item>
      <title>City Therapeutics seeks clinical trial clearance for CITY-FXI</title>
      <description>
        <![CDATA[City Therapeutics Inc. has submitted a clinical trial application (CTA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a phase I study of CITY-FXI, an investigational RNAi therapeutic targeting factor XI (FXI) for the treatment of thromboembolic diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726059</guid>
      <pubDate>Tue, 11 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726059-city-therapeutics-seeks-clinical-trial-clearance-for-city-fxi</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Thrombosis-blood-clot.webp?t=1676651893" type="image/png" medium="image" fileSize="1702000">
        <media:title type="plain">Illustration of clot forming in blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>UK MHRA sets out reforms to speed rare disease therapy approvals</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare products Agency (MHRA) has committed to major reforms of how it regulates drugs for rare diseases, making it easier to run clinical trials and get approvals. The new rules will be published in full early in 2026 and come into effect later in the year, but following consultation with industry, academics and patients’ groups, the agency has released a position paper setting out its plans.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725778</guid>
      <pubDate>Mon, 03 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725778-uk-mhra-sets-out-reforms-to-speed-rare-disease-therapy-approvals</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/UK-flag-on-stethoscope.webp?t=1602090629" type="image/png" medium="image" fileSize="394700">
        <media:title type="plain">U.K. flag on stethoscope</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA announces winners in AI Airlock challenge</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency reported the winners of the second phase of the AI Airlock challenge, which includes the Tortus AI, a medical scribe system developed by physicians in the U.K. National Health Service.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725132</guid>
      <pubDate>Mon, 20 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725132-mhra-announces-winners-in-ai-airlock-challenge</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Interconnected-nodes-representing-a-digital-supply-chain-network.webp?t=1760041474" type="image/jpeg" medium="image" fileSize="152302">
        <media:title type="plain">Interconnected nodes representing a digital supply chain network</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA vows to forge deeper ties with FDA</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) reported that it will seek to deepen its collaboration with other regulators, a list that includes but is not limited to the FDA. MHRA said that the U.K.-U.S. reliance program would apply to not only class II devices under the 510(k) and de novo programs, but to class III PMA devices as well, promising a somewhat more streamlined path to a market ripe with opportunity for the devices and diagnostics industries.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724831</guid>
      <pubDate>Fri, 10 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724831-mhra-vows-to-forge-deeper-ties-with-fda</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Digital-representation-of-U.S.-U.K.-flags.webp?t=1747081397" type="image/jpeg" medium="image" fileSize="231813">
        <media:title type="plain">Digital representation of U.S.-U.K. flags</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA jumps into personalized medicine with the ‘preference zone’</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency has decided to lean into personalized medicine with the adoption of the concept of a “preference zone” for determining when a therapy can and cannot be used for a specific patient, a concept that is liable to lead to more demanding postmarket surveillance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724488</guid>
      <pubDate>Thu, 02 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724488-mhra-jumps-into-personalized-medicine-with-the-preference-zone</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/UK-flag-and-capsules.webp?t=1617385565" type="image/png" medium="image" fileSize="333731">
        <media:title type="plain">U.K. flag and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA to launch clinical trial change pilot</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency announced a new pilot program for modifications to clinical trials that allows for automatic approvals of those changes based on the risks those changes present.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723549</guid>
      <pubDate>Tue, 02 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723549-mhra-to-launch-clinical-trial-change-pilot</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-flag-map.webp?t=1588688261" type="image/png" medium="image" fileSize="400329">
        <media:title type="plain">United Kingdom flag, map</media:title>
      </media:content>
    </item>
    <item>
      <title>UK’s MHRA seeks feedback on in-house device manufacturing</title>
      <description>
        <![CDATA[In a regulatory round-up, the U.K. Medicines and Healthcare Products Regulatory Agency opened a survey regarding in-house device manufacturing, the EU Notified Bodies staffed up last year and t<span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">he Singapore Health Sciences Authority and the Hong Kong Department of Health agreed to share information.</span>]]>
      </description>
      <guid>http://www.bioworld.com/articles/722857</guid>
      <pubDate>Thu, 14 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722857-uks-mhra-seeks-feedback-on-in-house-device-manufacturing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-flag-map.webp?t=1588688261" type="image/png" medium="image" fileSize="400329">
        <media:title type="plain">United Kingdom flag, map</media:title>
      </media:content>
    </item>
    <item>
      <title>UK MHRA highlights potential of the vaginal microbiome in women’s health</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare products Agency (MHRA) is calling for more research into the vaginal microbiome as a way to redress the historic under-representation of women in clinical studies, which it said has contributed to “critical shortcomings” in understanding of female-specific conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723338</guid>
      <pubDate>Wed, 13 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723338-uk-mhra-highlights-potential-of-the-vaginal-microbiome-in-womens-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-reproduction-ovaries-uterus-cervix.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="118515">
        <media:title type="plain">Illustration of women's reproductive organs</media:title>
      </media:content>
    </item>
    <item>
      <title>UK MHRA highlights potential of the vaginal microbiome in women’s health</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare products Agency (MHRA) is calling for more research into the vaginal microbiome as a way to redress the historic under-representation of women in clinical studies, which it said has contributed to “critical shortcomings” in understanding of female-specific conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723010</guid>
      <pubDate>Tue, 12 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723010-uk-mhra-highlights-potential-of-the-vaginal-microbiome-in-womens-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-reproduction-ovaries-uterus-cervix.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="118515">
        <media:title type="plain">Illustration of women's reproductive organs</media:title>
      </media:content>
    </item>
    <item>
      <title>Purespring gets go-ahead for first kidney-directed gene therapy</title>
      <description>
        <![CDATA[Purespring Therapeutics Ltd. has received the go-ahead for a phase I/II trial of its investigational gene therapy PS-002 from both the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the National Health Service Health Research Authority and Research Ethics Committee.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722900</guid>
      <pubDate>Tue, 05 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722900-purespring-gets-go-ahead-for-first-kidney-directed-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-edit-genomics.webp?t=1747837759" type="image/jpeg" medium="image" fileSize="1061729">
        <media:title type="plain">DNA double helix under a magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA eyes expanded reliance programs to boost patient access</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency unveiled another round of measures designed to promote access to the latest medical technology, which includes a move to jettison domestic device markings in favor of unique device identifiers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722079</guid>
      <pubDate>Tue, 22 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722079-mhra-eyes-expanded-reliance-programs-to-boost-patient-access</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/mhra-logo.webp?t=1707169524" type="image/jpeg" medium="image" fileSize="25893">
        <media:title type="plain">MHRA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>Life sciences strategy to reduce UK approval costs by 25%</title>
      <description>
        <![CDATA[The U.K. government has committed to reduce the cost of drug and device approvals by 25% as part of a long-awaited life sciences strategy which sets out a 10-year plan for the sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722356</guid>
      <pubDate>Thu, 17 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722356-life-sciences-strategy-to-reduce-uk-approval-costs-by-25</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-flag-map.webp?t=1588688261" type="image/png" medium="image" fileSize="400329">
        <media:title type="plain">United Kingdom flag, map</media:title>
      </media:content>
    </item>
    <item>
      <title>Life sciences strategy to reduce UK approval costs by 25%</title>
      <description>
        <![CDATA[The U.K. government has committed to reduce the cost of drug and device approvals by 25% as part of a long-awaited life sciences strategy which sets out a 10-year plan for the sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722165</guid>
      <pubDate>Wed, 16 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722165-life-sciences-strategy-to-reduce-uk-approval-costs-by-25</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/europe-uk-flag-map.webp?t=1588688261" type="image/png" medium="image" fileSize="400329">
        <media:title type="plain">United Kingdom flag, map</media:title>
      </media:content>
    </item>
    <item>
      <title>UK industry encourages renewal of rare disease framework</title>
      <description>
        <![CDATA[Representatives of patients’ groups, industry bodies and venture philanthropy funders are calling for a renewal of the U.K. Rare Diseases Framework, to put fresh momentum behind translational research and clinical trials, streamline regulatory oversight and improve access to therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721914</guid>
      <pubDate>Tue, 08 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721914-uk-industry-encourages-renewal-of-rare-disease-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/Rare-disease-illustration.webp?t=1603830564" type="image/png" medium="image" fileSize="378104">
        <media:title type="plain">Rare disease illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA tackles risk classification for digital mental health tech</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulator Agency dropped a guidance for digital mental health technologies that clarifies several key points, such as when the DMHT qualifies as software as a medical device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721644</guid>
      <pubDate>Thu, 03 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721644-mhra-tackles-risk-classification-for-digital-mental-health-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/thumb/mhra-logo.webp?t=1707169524" type="image/jpeg" medium="image" fileSize="26418">
        <media:title type="plain">MHRA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>UK’s MHRA first regulatory to join Health AI’s global regulator network</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency reported June 24 it joined a global regulatory network for AI that is part of the Health AI regulatory initiative &ndash; a program that will invite another nine regulatory agencies to take part in the initiative in the months ahead.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721138</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721138-uks-mhra-first-regulatory-to-join-health-ais-global-regulator-network</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-structure/Aging-digital-hourglass-futuristic.webp?t=1724944821" type="image/jpeg" medium="image" fileSize="320796">
        <media:title type="plain">Hourglass on glowing circuit board, symbolizing time and technology</media:title>
      </media:content>
    </item>
    <item>
      <title>UK launches pharmacogenomics project targeting GLP-1s</title>
      <description>
        <![CDATA[The increased use of GLP-1 receptor agonists has led on to an increase in reports of acute pancreatitis in people taking these weight loss drugs in the U.K. That has prompted the launch of a pharmacogenomics project to investigate if there are any genetic links underlying the occurrence of this adverse event.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721633</guid>
      <pubDate>Mon, 30 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721633-uk-launches-pharmacogenomics-project-targeting-glp-1s</link>
    </item>
    <item>
      <title>UK’s MHRA opens second round in AI airlock program</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulatory Agency opened a second round in its AI airlock program although this round, like the first round, will be limited to four applicants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721205</guid>
      <pubDate>Mon, 23 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721205-uks-mhra-opens-second-round-in-ai-airlock-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/thumb/mhra-logo.webp?t=1707169524" type="image/jpeg" medium="image" fileSize="26418">
        <media:title type="plain">MHRA logo</media:title>
      </media:content>
    </item>
  </channel>
</rss>
